JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after Pharmasset amended its phase 2b quantum trails this morning, rocking the boat of hepatitis C-related companies. "This announcement does not trigger a 'key product event' of the merger agreement. As such, we anticipate the deal will close on schedule."